MicroRNA-125b-1 (miR-125b-1) is a target of a chromosomal translocation t(11;14)(q24;q32) recurrently found in human B-cell precursor acute lymphoblastic leukemia (BCP-ALL). This translocation results in overexpression of miR-125b controlled by immunoglobulin heavy chain gene (IGH) regulatory elements. In addition, we found that six out of twenty-one BCP-ALL patients without t(11;14)(q24;q32) showed overexpression of miR-125b. Interestingly, four out of nine patients with BCR/ABL-positive BCP-ALL and one patient with B-cell lymphoid crisis that had progressed from chronic myelogenous leukemia overexpressed miR-125b. To examine the role of the deregulated expression of miR-125b in the development of B-cell tumor in vivo, we generated transgenic mice mimicking the t(11;14)(q24;q32) (El/miR-125b-TG mice). El/miR-125b-TG mice overexpressed miR-125b driven by IGH enhancer and promoter and developed IgM-negative or IgM-positive lethal B-cell malignancies with clonal proliferation. B cells obtained from the El/miR-125b-TG mice were resistant to apoptosis induced by serum starvation. We identified Trp53inp1, a proapoptotic gene induced by cell stress, as a novel target gene of miR-125b in hematopoietic cells in vitro and in vivo. Our results provide direct evidence that miR-125b has important roles in the tumorigenesis of precursor B cells.
Introduction
Chromosomal translocations involving the immunoglobulin heavy chain gene (IGH) locus have a pivotal role in the pathogenesis of human B-cell malignancies.
1,2 IGH translocation brings target genes positioned on different chromosome loci into close apposition with transcription elements within the IGH locus, resulting in deregulated expression of the target genes. The vast majority of the target genes physiologically act as key regulators in cell growth, differentiation, signal transduction or apoptosis of B cells. 1 Thus, deregulated expression of the translocated genes would alter B-cell fate leading to malignant transformation. MicroRNAs (miRNAs) are small non-coding RNAs that regulate protein synthesis through degradation of messenger RNAs or inhibition of translation. 3, 4 Many miRNAs are involved in a variety of important biological processes. Therefore, altered expression of miRNA affects cellular physiology and is responsible for some human disease. 5, 6 An evolutionally conserved miRNA, miR-125b, has been implicated in human cancers. [7] [8] [9] [10] [11] [12] MiR-125b-1, mapped on 11q24, has been found to be a target of recurrent chromosomal abnormalities seen in both lymphoid and myeloid malignancies. [7] [8] [9] [10] We previously reported an insertion of miR-125b-1 into the IGH locus in a patient with B-cell precursor acute lymphoblastic leukemia (BCP-ALL). 7 Subsequently, other groups identified fusion sequences of IGH and miR-125b-1 from t(11;14)(q24;q32). 9, 10 Bousquet et al. 8 identified miR-125b-1 as a gene involved in t(2;11)(p21;q23) observed in patients with myelodysplastic syndrome and acute myeloid leukemia (AML). This translocation is associated with upregulation of miR-125b from 6-to 90-fold. Recent studies show that ectopic expression of miR-125b in hematopoietic stem cells developed several hematological malignancies. [13] [14] [15] However, in vivo oncogenic activities of miR-125b in B cells have not been fully understood.
In the present paper, we report molecular cloning of a novel breakpoint of t(11;14)(q24;q32) from a BCP-ALL patient, and show that transgenic mice mimicking this translocation develop lethal B-cell malignancies. Overexpression of miR-125b confers an anti-apoptotic property on cells along with inhibition of a pro-apoptotic gene, Trp53inp1 (transformation-related protein 53 inducible nuclear protein 1), also known as TP53INP1, TEAP, SIP and p53DINP1, [16] [17] [18] [19] at the mRNA and protein levels. Of clinical relevance, we found overexpression of miR-125b in a variety of hematological malignancies. In particular, its overexpression in BCR/ABL-positive BCP-ALL supports the result showing the cooperative function of miR-125b in BCR/ABLinduced leukemia in an animal model. 14 
Materials and methods

Molecular analyses of patients showing fusion between IGH and miR-125b-1
A novel t(11;14)(q24;q32) breakpoint was cloned by long distant-inverse PCR as described. 20 An IGH/miR-125b-1 chimera transcript was yielded by reverse transcriptase-PCR (RT-PCR) using cDNA from leukemic cells of the insertion case. Primer pairs and conditions are described in 'Supplementary Materials and methods'.
Establishment of Em/miR-125b transgenic mice
A 422 bp of mouse genomic sequence including pre-miR-125b-1 was PCR amplified from C57BL/6 mouse genomic DNA. Primer pairs are described in 'Supplementary Materials and methods'. The fragment was inserted into the EcoRI site of pEm/IGH plasmid (a kind gift from Dr Akagi, Saitama Cancer Institute, Japan). After digestion with XbaI and SalI, the recombinant DNA was injected into 300 eggs at Unitech Laboratory (Chiba, Japan). Two F0 mice were successfully generated as stable TG mice and designated as TG116 and TG005.
Southern blot analysis of the IGHJ region of the Em/miR125b-TG mice
Ten micrograms of genomic DNA was digested using EcoRI and subjected to Southern blot analysis using a digoxigenin-labeled 1.2 kb EcoRI/HindIII fragment of pMJH4 (JCRB, Osaka, Japan) recognizing the mouse IGHJ region.
Flow cytometric analysis
Red blood cell-depleted cells were stained with fluorescein isothiocyanate-conjugated anti-B220 Ab (Miltenyi Biotec, Gladbach, Germany), fluorescein isothiocyanate-conjugated anti-CD43 Ab (BD Biosciences, San Jose, CA, USA) or phycoerythrin-conjugated anti-CD19, IgM, CD3 and CD11b Abs (all from eBioscience, San Diego, CA, USA). For the apoptosis assay, cells were stained with fluorescein isothiocyanate AnnexinV and Propidium Iodide (BD Biosciences). Flow cytometric analysis was performed as described.
21,22
Morphological analysis
Cytospin preparations of bone marrow (BM) cells or peripheral blood were stained with Giemsa. Images were obtained with a BX51 microscope and DP21 camera (Olympus, Tokyo, Japan). Formalin-fixed and paraffin-embedded sections were stained with hematoxylin-eosin and examined using a microscope (Axio Imager A1, Carl Zeiss, Jena, Germany) with an AxioCam camera and AxioVision 4.6 software (Carl Zeiss).
Purification of B220-positive cells
B220-positive cells of BM cells or splenocytes were selected using an anti-B220 bearing magnetic beads (CD45R (B220) MicroBeads; Miltenyi Biotec) and columns attached by magnetic fields (MACS Separation Columns; Miltenyi Biotec) according to the manufacturer's protocol.
Vector construction
MicroRNA expression fragments were cloned into pMXsEF1-(GFP), which were pMXs-based self-inactivating retrovirus vectors expressing miRNA under an EF1a promoter along with a BGH polyA site and expressing GFP under a PGK promoter along with a 3 0 long terminal repeat. A miRNA expression cassette was constructed in the opposite direction from a GFP expression cassette. Expression fragments of miR-125b or IGH/ miR-125b-1 were PCR amplified from C57BL/6 mouse genomic DNA or cDNA of tumor derived from a BCP-ALL patient, 7 respectively. Primer pairs are described in 'Supplementary Materials and methods'.
Real-time PCR
Total RNAs were treated with Deoxyribonuclease I (Invitrogen, Carlsbad, CA, USA) and reverse transcribed by using miScript Reverse Transcription Kit (QIAGEN, Hilden, Germany). Realtime PCR was performed using a LightCycler Workflow System (Roche Diagnostics, Mannheim, Germany). Mature miR-125b expression was measured using a miScript SYBR Green PCR kit (QIAGEN). cDNA was amplified with miR-125b-specific primers (QIAGEN). Expression of U6 small nuclear RNA, as an internal control, was used for normalization of the results. For mRNA real-time PCR, a SYBR Premix EX Taq (Takara, Shiga, Japan) was used as described. 23 Primer pairs are described in 'Supplementary Materials and methods'. Patients' informed consents were obtained in accordance with the Declaration of Helsinki, and the studies were approved by the ethics committees of Wakayama Medical University (approval no. 72-2009) and the University of Tokyo (approval no. 21-44-1224). Human blood, peripheral leukocytes total RNA (Clontech, Palo Alto, CA, USA) was used as a normal control. Total RNAs from peripheral blood of the patients were isolated using Mouse RiboPure-Blood RNA Isolation Kit (Ambion, Austin, TX, USA).
Luciferase assay
The 3 0 untranslated region (UTR) of the mouse Trp53inp1 was PCR amplified from C57BL/6 mouse genomic DNA. Primer pairs are described in 'Supplementary Materials and methods'. The 3 0 UTR was cloned to downstream of the Renilla luciferase stop codon in pGL4.74 vector (Promega, Madison, WI, USA). To generate the mutant 3 0 UTR of the mouse Trp53inp1, two-step PCR mutagenesis was performed [24] [25] [26] using the WT-3 0 UTR as a template. The Rluc-2 Â 125b site vector contained two copies of a sequence designed to be perfectly complementary to the miR125b downstream of the Renilla luciferase stop codon. 293T cells were co-transfected with the reporter vector (RLuc), miR125b expression vector, and a transfection control vector expressing firefly luciferase (pGL3-control) using Fugene 6. Cells were harvested 30 h post-transfection and assayed with Dual Luciferase Assay (Promega). Three independent experiments were performed with a triplicate set.
Western blot analysis
Equal numbers of cells were lysed and western blotting was performed as described. 22, 27, 28 Anti-Trp53inp1 Ab (ANASPEC, Fremont, CA, USA) and anti-ERK1/2 Ab (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used.
Results
Overexpression of miR-125b in patients with BCP-ALL
We found a new BCP-ALL patient with t(11;14)(q24;q32) and cloned the breakpoint. In this patient, the translocation resulted in breakage in JH6 of IGH on chromosome 14q32 and fusion to its 12.6 kb downstream of the miR-125b-1 locus on 11q24 ( Figure 1a ). The four breakpoints of the 11q24 so far identified by us and other groups 9, 10 
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Mock , P2 and P3 were previously reported. 9, 10 P4 is a novel case showing t(11:14)(q24:q32). The nucleotide sequence cloned from P4 is shown. (b) The genome and chimera transcript structure observed in the insertion case. 7 RT-PCR using primers set at VH and Cm produced two PCR products (390 and B170 bp). (c) Relative expression levels of miR125b were examined by real-time PCR in 293T cells transduced with pMXsEF1-IGH/miR-125b-1-(GFP), miR-125b expression vector (pMXsEF1-miR-125b-(GFP)) or mock (pMXsEF1-(GFP)). Data represent the average of two independent experiments. (d) Renilla luciferase (RLuc) vector or Rluc-2 Â 125b site vector containing two copies of a sequence designed to be perfectly complementary to the miR-125b was co-transfected into 293T cells with a transfection control vector expressing firefly luciferase (pGL3 control) and pMXsEF1-IGH/miR-125b-1-(GFP), pMXsEF1-miR125b-(GFP) or mock (pMXsEF1-(GFP)). Luciferase assays were performed with a triplicate set. (e) Relative expression levels of miR-125b were examined by real-time PCR in peripheral blood cells derived from patients with hematological diseases. Data represent the mean values ± s.e.m. of two independent experiments. P-values (*) of o0.05 were considered significant using a Student's two-tailed t-test. All data were representative of three independent experiments. 7 The genomic structure of the IGH allele inserted by pri-miR-125b-1 sequence is shown in Figure 1b . RT-PCR using primer settings at VH and Cm yielded 390 bp of chimera transcript consisting of VH, pri-miR-125b-1, DH, JH and Cm, and B170-bp product (Figure 1b ; Supplementary Figure 1 ). Sequence analysis of the B170-bp product revealed divers nucleotide alignments consisting of a VH/DH/ JH/Cm complex sequence, suggesting that this PCR product might originate from polyclonal B cells existing in the tumor sample. To examine whether this chimera transcript could produce mature miR-125b, we cloned the chimera sequence from the cDNA derived from the tumor cells into pMXsEF1-(GFP) (hereafter pMXsEF1-IGH/miR-125b-1-(GFP)). Real-time PCR confirmed that the cells transduced with pMXsEF1-IGH/ miR-125b-1-(GFP), as well as a positive control, expressed miR-125b (Figure 1c) . Furthermore, luciferase assay showed that miR-125b produced from IGH/miR-125b-1 repressed the activity of the reporter construct (Rluc-2 Â 125b site) containing two copies of a sequence designed to be perfectly complementary to miR-125b (Figure 1d ). These results demonstrated that the IGH allele inserted by the miR-125b-1 sequence produces miR-125b when the promoter and enhancer are active.
MicroRNA
For further analysis of the clinical relevance of miR-125b in hematological diseases, we examined expression of miR-125b in hematological tumors obtained from twenty-one BCP-ALL, eight AML, four chronic myelogenous leukemia, seven myelodysplastic syndrome, three myeloproliferative neoplasm and four polycythemia vera patients (Figure 1e ; Supplementary  Tables 1 and 2 ). We found that miR-125b was overexpressed in various patients; six BCP-ALL, five AML, two chronic myelogenous leukemia (accelerated phase and B-lymphoid blast crisis), one myeloproliferative neoplasm and two myelodysplastic syndrome patients showed more than fivefold higher expression of miR-125b compared with normal samples. Of note, miR-125b was highly expressed in four out of nine t(9;22)(q34;q11) positive BCP-ALL and one B-lymphoid blast crisis derived from chronic myelogenous leukemia.
We also investigated expression of miR-125a possessing the same seed sequence as that of miR-125b in these patients (Supplementary Figure 2) . We found that one BCP-ALL patient showed more than fivefold higher expression of miR-125a compared with normal samples. These results indicate that overexpression of miR-125a in hematological malignancies is infrequent.
Em/miR-125b-TG mice developed lethal lymphoid malignancies
We next generated Em/miR-125b-TG mice to investigate whether deregulated expression of miR-125b could be responsible for the development of B-cell malignancy in vivo. The transgene consisted of human intronic enhancer of IGH (Em), mouse VH promoter and rabbit b-globin-including mouse genomic sequence containing pre-miR-125b ( Supplementary  Figure 3a) . Since the VH promoter and the Em enhancer become active at the late pro-B cell stage, 29 miR-125b is thought to be expressed at this differentiation stage. We examined two TG lines, designated as Em/miR-125b-TG116 (TG116) and Em/miR125b-TG005 (TG005). Southern blot analysis using a transgenespecific probe showed different patterns of integration, suggesting that a high copy number was introduced in TG116 compared with TG005 (Supplementary Figure 3) . We confirmed expression of miR-125b in both TG mice (Figure 2a ). All TG116 mice developed lethal lymphoid tumors within 35 weeks whereas five out of thirteen TG005 mice died within 50 weeks with a disease similar to that of TG116 (Figure 2b) . When the disease became overt, both TG116 and TG005 mice showed splenomegaly (Figure 2c; Supplementary Figure 4) . Moreover, TG116 mice showed hepatomegaly and an increased number of BM cells, whereas the concentration of hemoglobin (Hb) of both TG116 and TG005 mice decreased compared with that of wildtype (WT) mice with statistical significance (Supplementary  Figure 4) .
Tumor cells with morphologically lymphoblastic features appeared in BM and peripheral blood (Figure 2d ). Histological examination showed that atypical lymphoid cells filled the spleen and infiltrated the liver (Figure 2d) . Using flow cytometric analysis, we found that nine morbid TG116 mice had developed IgM À precursor B-cell tumors, one IgM þ B-cell tumor and one T-cell tumor, whereas four morbid TG005 mice had developed IgM þ B-cell tumors and one IgM þ /B220 À tumor (Figure 2e and data not shown). Flow cytometric analysis delineated that most tumor cells of the morbid TG116 mice consisted of B220 þ / CD19 þ /IgM À /CD43 þ B cells, whereas those of the morbid TG005 mice were B220
þ B cells increased in the TG116 mice as early as 4 weeks mice (Supplementary Figure 5a) . To examine the tumor clonality, we performed Southern blot analysis; we detected rearranged bands in eight out of nine morbid TG116 mice and in all the five morbid TG005 mice, indicating clonal proliferation of B cells (Figure 2f and data not shown). One out of four young TG116 mice showed clonal rearranged bands before the onset of the disease, suggesting that clonal proliferation can occur even in 4 weeks after birth (Supplementary Figure 5b) . Collectively, Em/miR-125b-TG mice developed lethal IgM À or IgM þ B-cell malignancies with clonal expansion.
MiR-125b inhibited apoptosis of hematopoietic cells
We next analyzed the mechanism by which miR-125b promoted leukemogenesis in vivo. To identify target genes of miR-125b, we performed a bioinformatics search using Targetscan (http://www.targetscan.org/). There were some apoptosisrelated genes, such as Bak1, Bmf, KLF13, MCL-1 and Trp53inp1, among the candidate target genes of miR-125b. In addition, we performed microarray analysis of 32Dcl3 cells transduced with miR-125b or mock. In microarray analysis, we found that among the candidate target genes the expression levels of Trp53inp1 mRNAs were reduced in 32Dcl3 cells transduced with miR-125b (data not shown). The 3 0 UTR of Trp53inp1 contained one putative target site that matched the seed sequences of miR-125b. Trp53inp1 is a pro-apoptotic gene induced by cell stress, [16] [17] [18] [19] and its repression is involved in tumorigenesis. 30, 31 To confirm that Trp53inp1 is a direct target gene of miR-125b, the wild-type 3 0 UTR of Trp53inp1 or the mutated 3 0 UTR was cloned to downstream of the Renilla luciferase open reading frame (Figure 3a) . We performed luciferase assays and found that miR-125b directly represses the expression of the reporter gene with the Trp53inp1-3 0 UTR but not that with mutated 3 0 UTR of Trp53inp1 (Figure 3a) . We then examined the expression levels of Trp53inp1 mRNAs in 32Dcl3 cells at different time intervals after inducing apoptosis by IL-3 withdrawal (Supplementary Figure 6a) . We found that the expression levels of Trp53inp1 mRNAs increased after inducing apoptosis by IL-3 withdrawal but that those of Trp53inp1 mRNAs were repressed in miR-125b-transduced 32Dcl3 cells compared with mock-transduced 32Dcl3 cells at each time point. In addition, the numbers of apoptotic cells decreased in miR-125b-transduced cells but not in miR-30a, Figure 6b) . Moreover, expression levels of mature miR-125b and Trp53inp1 mRNA were inversely correlated. With one exception (Figure 3b, lane 10) , TG116 mice tended to express lower levels of Trp53inp1 at the mRNA and protein levels compared with WT mice (Figures 3b and c) . We also found that B220-positive splenocytes derived from TG116 mice became resistant to apoptosis induced by serum starvation when compared with WT mice (Figure 3d) . Collectively, these results indicated that miR-125b inhibits apoptosis of hematopoietic cells at least partly through repressing Trp53inp1.
Discussion
A number of miRNAs are located on regions of the genome involved in chromosome alteration, such as deletion, amplification and translocation as observed in various malignant tumors. 5, 6 Although cloned chromosomal translocations involving IGH loci are common genomic alterations in B-cell malignancies, only miR-125b-1 has so far been shown to be a target miRNA related to IGH translocations. In the present paper, we report a new patient with t(11;14)(q24;q32) and direct evidence for the oncogenic potential of miR-125b in B cells using transgenic mice mimicking the translocation. 1-3) . Lysates were immunoblotted with anti-Trp53inp1 Ab or anti-ERK1/2 Ab as a control. Relative band intensities of Trp53inp1 were calculated by densitometric analysis and normalized to ERK1/2. (d) Purified B220-positive splenocytes of 20-weekold TG116 or WT mice were cultured without serum. Cells were stained with fluorescein isothiocyanate AnnexinV and Propidium Iodide. P-values (*) of o0.05 were considered significant using a Student's two-tailed t-test. All data were representative of three independent experiments.
MicroRNA-125b is implicated in leukemia Y Enomoto et al
Overexpression of miR-125b in BM cells was reported to induce myeloproliferative neoplasm in transplanted mice that progressed to AML, 13 while BM-derived highly purified hematopoietic stem cells overexpressing miR-125b tended to differentiate into lymphoid lineages after transplantation. 15 On the other hand, half of the mice transplanted with miR-125b-overexpressing fetal liver hematopoietic stem cells developed T-ALL, B-ALL or myeloproliferative neoplasm.
14 These report indicated that miR-125b has important roles in proliferation and differentiation of hematopoietic stem cells. However, the functions of miR-125b in B cells have remained elusive.
In the present paper, we have shown that overexpression of miR-125b triggered by IGH enhancer and promoter induces two different types of lethal B-cell malignancies. TG116 mice mainly develop faster-onset IgM-negative tumors and TG005 mice develop slower-onset IgM-positive tumors. This difference could be explained by expression levels of miR-125b due to the different copy number of transgenes integrated into mouse chromosome (Supplementary Figure 3b) . Alternatively, other factors such as epigenetic changes or inhibition of other miRNAs might have been involved in the development of the disease and were responsible for the difference in the disease phenotypes.
MiR-125 was suggested to confer anti-apoptotic characteristics on cells by reducing expression levels of apoptosisinducing genes such as Bak1, Bmf and KLF13 in mouse hematopoietic cells. 15, 32 In this study, we have identified Trp53inp1 as a novel candidate of the miR-125b target gene in mice; its mRNA and protein levels decreased in B220-positive cells obtained from Em/miR-125b-TG mice. Indeed, Trp53inp1 null mice were shown to be susceptible to cancer development. 31 Of clinical relevance, we found that miR-125b was overexpressed in various hematopoietic diseases including BCP-ALL, AML and myelodysplastic syndrome without chromosomal translocations, t(11;14)(q24;q32) or t(2;11)(p21;q23). Mature miR-125b is also produced from miR-125b-2 mapped on 21q21. However, the above-mentioned patients except for a BCP-ALL patient ID 7 showed no abnormalities of chromosome 21 (Supplementary Tables 1 and 2 ). These cases may express high amount of miR-125b by unknown mechanisms. Interestingly, we reported here that four out of nine BCR/ABL-positive ALL patients and one with B-cell lymphoid crisis of chronic myelogenous leukemia showed high expression levels of miR125b. Another group also independently found overexpression of miR-125b in a BCR/ABL-positive ALL patient lacking t(11;14)(q24;q32). 9 Recently, it was reported that miR-125b can cooperate in leukemogenic activity with BCR/ABL. Taking clinical and experimental results together, overexpression of miR-125b would be associated with hematological malignancies. As inactivation of oncomiR, such as miR-21, can decrease tumorigenesis, 33 inhibition of miR-125b could be a new strategy for treatment of hematopoietic malignancies. Our transgenic mice will be a useful tool in the development of the therapy for the patients with high miR-125b expression.
